-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On February 24, the official website of CDE showed that the clinical application for Junshi Bio-JS201 injection was accepted.
According to the information officially disclosed by Junshi, the PD-1 antibody of JS201 is partly based on teriprizumab.
Previously, Merck’s PD-L1/TGFβ dual-antibody M7824 showed good efficacy in the subsequent treatment of multiple cancers such as non-small cell lung cancer and cholangiocarcinoma, and received an advance payment of US$340 million from GlaxoSmithKline+37 The introduction of a milestone amount of 100 million US dollars, a number of factors have ignited the enthusiasm for research and development in this field, and many companies have deployed PD-L1/TGFβ dual antibodies; however, in January this year, Merck decided to terminate the project based on phase III clinical data of non-small cell lung cancer.
At present, for the PD-L1/TGFβ target, domestic Hengrui Pharmaceuticals and Pumis Biologics have entered the clinic, with Hengrui being the fastest, and it is in clinical phase II; the pre-clinical development companies include Chuangsheng Group, Zejing Pharmaceutical, Lijin Biology, Lepu Biology, Hebo Pharmaceutical, Weilizhibo, Changchun Jinsai.
